4.7 Review

Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery

期刊

ADVANCED HEALTHCARE MATERIALS
卷 10, 期 8, 页码 -

出版社

WILEY
DOI: 10.1002/adhm.202001812

关键词

DNA; mRNA; nanoparticles; nucleic acid; vaccine delivery; vaccines

资金

  1. American Heart Association [19AIREA34380849]
  2. National Science Foundation [2001606]
  3. Interdisciplinary Program of Shanghai Jiao Tong University [ZH2018ZDA36 (19 x 190020006)]
  4. Shanghai Jiao Tong University Scientific and Technological Innovation Funds [2019TPA10]
  5. Div Of Chem, Bioeng, Env, & Transp Sys
  6. Directorate For Engineering [2001606] Funding Source: National Science Foundation

向作者/读者索取更多资源

Nucleic acid vaccines hold promise as an immunization method for combating pandemics, with nanoparticles being a top candidate for successful DNA/mRNA vaccine delivery due to their unique properties.
Nucleic acid vaccines are a method of immunization aiming to elicit immune responses akin to live attenuated vaccines. In this method, DNA or messenger RNA (mRNA) sequences are delivered to the body to generate proteins, which mimic disease antigens to stimulate the immune response. Advantages of nucleic acid vaccines include stimulation of both cell-mediated and humoral immunity, ease of design, rapid adaptability to changing pathogen strains, and customizable multiantigen vaccines. To combat the SARS-CoV-2 pandemic, and many other diseases, nucleic acid vaccines appear to be a promising method. However, aid is needed in delivering the fragile DNA/mRNA payload. Many delivery strategies have been developed to elicit effective immune stimulation, yet no nucleic acid vaccine has been FDA-approved for human use. Nanoparticles (NPs) are one of the top candidates to mediate successful DNA/mRNA vaccine delivery due to their unique properties, including unlimited possibilities for formulations, protective capacity, simultaneous loading, and delivery potential of multiple DNA/mRNA vaccines. This review will summarize the many varieties of novel NP formulations for DNA and mRNA vaccine delivery as well as give the reader a brief synopsis of NP vaccine clinical trials. Finally, the future perspectives and challenges for NP-mediated nucleic acid vaccines will be explored.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据